Is 'Walker 2006' a real study?

The paper is Teichman and colleagues, JCEM 2006. The Walker attribution appears to be an error that entered circulation and is preserved only in this page's URL.

What did the study show?

Prolonged GH and IGF-I secretion in healthy adults after CJC-1295 with DAC, establishing that covalent albumin binding produces sustained activity.

Does it show a clinical benefit?

No. It is a pharmacokinetic and pharmacodynamic study, not an outcome trial.

The Teichman 2006 CJC-1295 Study

The short answer

Teichman and colleagues reported prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults in the Journal of Clinical Endocrinology and Metabolism in 2006. It remains the principal peer-reviewed reference for the DAC formulation.

Key facts

Correct citation: Teichman SL et al., JCEM 2006
PMID: 16352683
Population: Healthy adults
Compound: CJC-1295 with DAC
Measured: GH and IGF-I secretion over time
Companion study: Ionescu & Frohman, JCEM 2006 (PMID 17018654)

The citation problem in this article's own URL

This page's address contains walker-2006, which is a misattribution carried over from an earlier version. The study is Teichman and colleagues. The URL is preserved because changing it would break existing links, but the attribution is corrected here. The mismatch is a reasonable illustration of how a wrong citation propagates once it enters circulation.

What the study reported

Prolonged stimulation of growth hormone and insulin-like growth factor I secretion following CJC-1295 with DAC in healthy adults. The significance is pharmacokinetic: it demonstrated that covalent albumin binding produced sustained GHRH-agonist activity over days rather than the minutes native GHRH achieves.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £36.99

Why it is the reference that matters

Most compounds in this library have no controlled human pharmacokinetic data at all. This study provides it for the DAC form, in healthy volunteers, published in a mainstream endocrinology journal. That is a considerably stronger evidential base than the rodent-only literature supporting most research peptides.

The companion finding

Ionescu and Frohman published in the same journal in the same year on whether pulsatile GH secretion persists during continuous stimulation, reporting that it does. Read together, the two papers describe what a long-acting GHRH analogue achieves and what the pituitary does with it: sustained exposure, but rhythm imposed by the gland rather than the input.

What it does not establish

Any outcome. Demonstrating that a compound raises GH and IGF-I over a period is pharmacodynamics, not a clinical result. CJC-1295 holds no marketing authorisation, and nothing in this study speaks to body composition, recovery or any other endpoint in any person.

Frequently asked questions

Is 'Walker 2006' a real study?: The paper is Teichman and colleagues, JCEM 2006. The Walker attribution appears to be an error that entered circulation and is preserved only in this page's URL.
What did the study show?: Prolonged GH and IGF-I secretion in healthy adults after CJC-1295 with DAC, establishing that covalent albumin binding produces sustained activity.
Does it show a clinical benefit?: No. It is a pharmacokinetic and pharmacodynamic study, not an outcome trial.

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release. CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
▸Ghrelin-receptor binding assays for Ipamorelin analogue development
▸Analytical HPLC method development for lipidated GHRH analogues
▸Stability testing under refrigerated storage

Handling checklist

✓Store lyophilised at −20 °C long-term
✓Reconstitute in bacteriostatic water; both peptides dissolve readily
✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
✓Do not use for human administration (research reference only)

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA. The two have very different pharmacokinetics.

✗ Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a), a separate pathway from CJC-1295.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum